RALEIGH, N.C., Oct. 22, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a development-stage biopharmaceutical company, today announced that it has received notification from The NASDAQ Stock Market indicating that the Company has demonstrated compliance with the $2.5 million stockholders’ equity requirement set forth in NASDAQ Listing Rule 5550(b). As a result, the Company’s securities will continue to trade on The NASDAQ Capital Market.
